Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News

Core Insights - David Novack, President & COO of Dynavax Technologies Corporation, exercised 114,000 stock options and sold the shares for approximately $1.8 million, reflecting significant insider activity [1][9] Transaction Summary - Shares sold directly: 114,000 [2] - Transaction value: $1.8 million [2] - Post-transaction shares held directly: 63,344 [2] - Post-transaction value of direct ownership: ~$989,433.28 [2] - Transaction value based on weighted average purchase price: $15.64 [2] - Market close price on Jan. 15, 2026: $15.62 [2] Company Overview - Market capitalization: $1.82 billion [4] - Revenue (TTM): $330.51 million [4] - Net income (TTM): -$43.40 million [4] - 1-year price change: 25.16% [4] Stake Reduction - Novack's stake reduced to 63,344 shares, equating to 0.05% of the company's outstanding shares as of Jan. 24, 2026 [6] - The transaction involved a full conversion from options to common stock without retention of new shares [6] Historical Context - The size of Novack's exercise and sale significantly exceeded his median sell transaction of 30,000 shares in the recent period [6] Company Profile - Dynavax Technologies Corporation is a specialty biopharmaceutical company focused on innovative vaccine development [8] - Core product: HEPLISAV-B, a hepatitis B vaccine for adults, utilizing proprietary adjuvant technology (CpG 1018) [8] - Revenue generation through vaccine sales and collaborations with pharmaceutical partners [7][8]